Skip to content

Effect of Warming Needle Moxibustion at Zhongji and Guanyuan Points in Female Patients with Diminished Ovarian Reserve

Effect of Warming Needle Moxibustion at Zhongji and Guanyuan Points in Female Patients with Diminished Ovarian Reserve

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000298
Enrollment
Unknown
Registered
2025-02-16
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve

Interventions

Control group:Drug therapy of complex packing estradiol tablets/estradiol and dydrogesterone tablets
Experimental group:Warming Needle Moxibustion at Zhongji and Guanyuan Points

Sponsors

Shanghai Research Institute of Acupuncture and Meridian
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Women aged ranged from 18 to 40 years old; 2. Meet the western diagnostic criteria for diminished ovarian reserve 10mlU/ml < follicle stimulating hormone (FSH) < 25 mlU/ml and antimullerian hormone (AMH) < 1.1 ng/ml; 3. Understand and agree to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with ophorectomy hysterectomy ovarian tumors or those with combined organic lesions of the reproductive organs; 2. Those who have combined serious primary diseases such as cardiovascular cerebrovascular hepatic renal and hematopoietic systems or those who suffer from non-serious diseases but need to be maintained with medication; 3. Pregnant or lactating women or female patients who have recently prepared for pregnancy; 4. Those who applied hormonal or immunosuppressive drug therapy within 3 months prior to participation in this study; 5.Those with known contraindications to acupuncture treatment such as having spontaneous bleeding or bleeding that does not stop after an injury having infections ulcers or tumors on the skin or those with a known drug allergy to complex packing estradiol tablets/estradiol and dydrogesterone tablets; 6. Those who have participated or are participating in other clinical trials within 1 month prior to participation in this study.

Design outcomes

Primary

MeasureTime frame
Follicle stimulating hormone (FSH);

Secondary

MeasureTime frame
Prolactin (P);Ultrasound of uterus and adnexa;Testosterone (T);Estradiol(E2);Antimullerian hormone (AMH);Syndrome score;Progesterone (P);Luteinizing hormone (LH);Menstrual score;

Countries

China

Contacts

Public ContactXu Mingshu

Shanghai Research Institute of Acupuncture and Meridian

mingshuxu@163.com+86 136 1189 9928

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026